Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Preparation of rabies vaccine for human being

A protein vaccine, rabies virus technology, applied in medical preparations containing active ingredients, antibody medical ingredients, antiviral agents, etc. safety effect

Inactive Publication Date: 2013-07-03
SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It contains components that have nothing to do with antigens, such as viral miscellaneous proteins, viral nucleic acids and lipids, and residual proteins of tissue proteins from cultured viruses. When the antigen content of the virus is increased, these miscellaneous proteins also increase, so the side effects of the vaccine are enlarged

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Human rabies virus particle split protein (mainly containing the outer membrane fragment of split virus particles), tetanus toxoid stock solution (Wuhan Institute of Biological Products), aluminum phosphate adjuvant, the mixing ratio according to the antigen content is: viral protein 5-100μg / dose; the dosage of tetanus toxoid is 2Lf / dose-10Lf / dose; aluminum phosphate adjuvant is 0.5mg / dose. The combination is made into a liquid vaccine, then packaged, and finally packaged for inspection.

Embodiment 2

[0023] The mice were immunized with the four combined vaccines of the method in Example 1 above, 0.5 ml each time, twice on day 0 and day 7, and blood was collected after 14 days of observation to detect serum neutralizing antibodies and titers.

[0024] Table 1

[0025] Vaccine Type

[0026] Therefore, it is shown that the aluminum phosphate adjuvant can significantly increase the potency of the rabies vaccine and enhance immunity, and can greatly reduce the amount of antigen in the purified stock solution of human rabies in the preparation of the vaccine, and has good protective effect.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides rabies vaccine for human being. The vaccine comprises an outer membrane segment of cracked rabies complete viral particles and tetanus toxoid, and the outer membrane segment comprises spike and matrix protein. Each dose of the rabies vaccine comprises 10 to 100 micrograms of viral protein; the dosage of the tetanus toxoid is 2 Lf / dose to 10 Lf / dose; and the dosage of aluminum phosphate adjuvant is 0.5mg / dose. Compared with the existing virus purified stock solution, the rabies vaccine for human being has the advantages that the content of impurity protein is greatly reduced, the immunogenicity and the potency are high, and the rabies vaccine is safer to use.

Description

technical field [0001] The invention relates to the field of medical prevention, in particular to a human rabies vaccine. Background technique [0002] Rabies is an acute infectious disease caused by rabies virus infection, and is a zoonotic acute infectious disease. Rabies kills more than 50,000 people each year, with 99 percent of deaths occurring in Asia, Africa and South America. [0003] Rabies virus (RV) is a highly neurotropic virus. It is a non-segmented negative-strand RNA virus in the rhabdoviridae family Rhabdovirus. Stranded RNA, the pathogen that causes rabies. Rabies virus has two main antigens: one is the glycoprotein antigen on the outer membrane of the virus, which can bind to the acetylcholine receptor to make the virus neurotoxic, and to produce neutralizing antibodies and hemagglutination inhibitory antibodies in the body. role; the other is the inner nuclear protein antigen, which can make the body produce complement-fixing antibodies and precipitins,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/295A61K39/205A61P31/14A61K39/08
Inventor 沈琼张高峡
Owner SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com